IL17A and myeloid sarcoma: In patients with MS, the levels of inflammatory cytokines, such as TNF-α and IL-17, increased significantly, while those of anti-inflammatory mediators IL-1ra and the chemokines IL-8, Eotaxin, RANTES, MIP-1a, MIP-1b, and MCP-1 decreased.